225Ac-RYZ-801
- Generic Name
- 225Ac-RYZ-801
Radiopharmaceuticals: The Next Frontier in Precision Oncology as Big Pharma Competes for Market Share
• Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.
• Major pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Bayer are aggressively entering the space through acquisitions and pipeline development, targeting a market projected to reach $16 billion by 2033.
• Innovation is focused on advancing from beta to more powerful alpha-emitting isotopes like actinium-225, improving targeting mechanisms, expanding into earlier treatment settings, and exploring combination therapies to enhance efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath